Hainan Huluwa Pharmaceutical Group (SHA:605199) said subsidiary Guangxi Weiwei's production facilities met the requirements of good manufacturing practice.
Guangxi Weiwei received a good manufacturing practice compliance inspection result from the Guangxi Zhuang Autonomous Region's drug administrator, according to a Wednesday filing with the Shanghai bourse.
Passing the inspection is conducive to the company's continued guarantee of product quality and stable production capacity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments